In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, capecitabine was added to the complementary list of the EML for use in treatment protocols for metastatic breast cancer. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for metastatic breast cancer is attached.